New HQ for developer of world's first fully automated drug discovery platform
End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.
Arctoris, the developer of the world’s first fully automated drug discovery platform, has opened the doors to its new global headquarters and R&D facility in Oxford, UK. Housing the company’s proprietary technology and providing space for its rapidly growing commercial and scientific teams, the facility will enable Arctoris to continue to support its research partners around the world with its structured, automated approach to drug discovery.
At the heart of the new scientific facility is the next-generation, fully automated platform developed by the drug discovery experts, engineers and roboticists at Arctoris. The platform efficiently generates reproducible data from biochemical, cell-based and molecular biology assays. The rapid turnaround enables shorter cycle times – and therefore more design-make-test-analyse iterations – for their drug discovery partners. This end-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data – all through an online portal that streamlines experiment planning, ordering, tracking and data analysis.
Martin-Immanuel Bittner, Chief Executive Officer and Co-Founder of Arctoris, said: “Investing in new global headquarters and greatly enhanced R&D facility in our home city of Oxford, UK, an internationally-renowned centre of scientific excellence, demonstrates our continued commitment to delivering the highest standards of data available to our partners. This state-of-the-art home for our next-generation robotic platform enables our growing team of experts to provide scientists across the globe with access to reproducible data through a rapid and fully-validated approach to drug discovery.”
Having settled into its new headquarters, Arctoris will continue delivering high quality, reproducible drug discovery data to its customers through access to a library of validated drug discovery protocols designed to support hit-to-lead analysis, lead optimisation, mechanistic profiling and additional preclinical studies. This will enable scientists to make rapid, informed decision-making in basic biology, target validation, toxicology and phenotypic screening for drug characterisation, optimisation and selection.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.